Chronic liver disease in children with leukemia in long-term remission.
Liver disease during chemotherapy and after its completion was studied in 103 leukemic children in long-term remission. Seventy developed chronic liver disease during therapy; 22 out of 56 with adequate follow-up showed persisting abnormality or deterioration of liver function after stopping therapy. In 38 studied prospectively, biopsies were obtained at treatment withdrawal. Five showed chronic lobular, 17 chronic persistent, 9 chronic active hepatitis whereas 7 had minimal changes. These children had transiently detectable serum hepatitis-B virus (HBV) markers during (44.4%), at completion of (7.8%) and subsequent to (48.3%) chemotherapy. Serum HBV markers correlated significantly with both severity of histologic changes (P less than 0.05) and persistent biochemical abnormalities for over 6 months after treatment suspension (P less than 0.001). No direct relationship was found between drug administration and liver damage. The data from the study suggest that in leukemic children viral infections contribute to chronic liver damage, which can jeopardize the long-term prognosis of acute leukemia.
D000208:Acute Disease; D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000201:enzymology / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000150:complications / Q000188:drug therapy; D008107:Liver Diseases / Q000150:complications*; D008297:Male; D011379:Prognosis; D013997:Time Factors; D000637:Transaminases / Q000032:analysis
D000970:Antineoplastic Agents; D006514:Hepatitis B Surface Antigens; D000637:Transaminases